T. Rowe Price Associates’s Xeris Biopharma Holdings XERS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $1.36M | Buy |
|
|||||
|
2025
Q3 | $1.36M | Buy |
|
|||||
|
2025
Q2 | $716K | Sell |
|
|||||
|
2025
Q1 | $969K | Buy |
|
|||||
|
2024
Q4 | $578K | Buy |
|
|||||
|
2024
Q3 | $459K | Buy |
|
|||||
|
2024
Q2 | $295K | Buy |
|
|||||
|
2024
Q1 | $278K | Buy |
|
|||||
|
2023
Q4 | $271K | Buy |
|
|||||
|
2023
Q3 | $210K | Buy |
|
|||||
|
2023
Q2 | $290K | Sell |
|
|||||
|
2023
Q1 | $201K | Hold |
|
|||||
|
2022
Q4 | $164K | Buy |
|
|||||
|
2022
Q3 | $162K | Buy |
|
|||||
|
2022
Q2 | $56K | Buy |
|
|||||
|
2022
Q1 | $61K | Buy |
|
|||||
|
2021
Q4 | $37K | Sell |
|
|||||
|
2021
Q3 | $158K | Buy |
|
|||||
|
2021
Q2 | $232K | Buy |
|
|||||
|
2021
Q1 | $223K | Buy |
|